Seminars in Hematology
Volume 41, Issue 1 , Pages 48-59 , January 2004

Plasma therapy in thrombotic thrombocytopenic purpura: review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiency

  • Stefano Fontana

      Affiliations

    • Central Hematology Laboratory, Inselspital, University Hospital, Bern, Switzerland
    • ,
  • Johanna A Kremer Hovinga

      Affiliations

    • Central Hematology Laboratory, Inselspital, University Hospital, Bern, Switzerland
    • ,
  • Jan-Dirk Studt

      Affiliations

    • Central Hematology Laboratory, Inselspital, University Hospital, Bern, Switzerland
    • ,
  • Lorenzo Alberio

      Affiliations

    • Central Hematology Laboratory, Inselspital, University Hospital, Bern, Switzerland
    • ,
  • Bernhard Lämmle

      Affiliations

    • Central Hematology Laboratory, Inselspital, University Hospital, Bern, Switzerland
    • ,
  • Behrouz Mansouri Taleghani

      Affiliations

    • Corresponding Author InformationAddress correspondence to Behrouz Mansouri Taleghani, MD, Central Hematology Laboratory, Inselspital, University Hospital, CH-3010 Bern, Switzerland
    • Central Hematology Laboratory, Inselspital, University Hospital, Bern, Switzerland

References 

  1. Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura (report of 16 cases and review of the literature). Medicine (Baltimore). 1966;45:139–159
  2. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, et al.  Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325:393–397
  3. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med. 1991;325:398–403
  4. Hénon P. Treatment of thrombotic thrombopenic purpura. Results of a multicenter randomized clinical study. Presse Med. 1991;20:1761–1767
  5. Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries (A hitherto undescribed disease). Proc NY Pathol Soc. 1924;24:21–24
  6. Moschcowitz E. An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries. Arch Intern Med. 1925;36:89–93
  7. Rubinstein MA, Kagan BM, MacGillviray MH, Merliss R, Sacks H. Unusual remission in a case of thrombotic thrombocytopenic purpura syndrome following fresh blood exchange transfusions. Ann Intern Med. 1959;51:1409–1419
  8. Bukowski RM, King JW, Hewlett JS. Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura. Blood. 1977;50:413–417
  9. Byrnes JJ, Khurana M. Treatment of thrombotic thrombocytopenic purpura with plasma. N Engl J Med. 1977;297:1386–1389
  10. Shepard KV, Bukowski RM. The treatment of thrombotic thrombocytopenic purpura with exchange transfusions, plasma infusions, and plasma exchange. Semin Hematol. 1987;24:178–193
  11. Shumak KH, Rock GA. Therapeutic plasma exchange. N Engl J Med. 1984;310:762–771
  12. Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996;87:4223–4234
  13. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood. 1996;87:4235–4244
  14. Furlan M, Robles R, Solenthaler M, Lämmle B. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood. 1998;91:2839–2846
  15. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, et al.  Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339:1578–1584
  16. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585–1594
  17. Gerritsen HE, Robles R, Lämmle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood. 2001;98:1654–1661
  18. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood. 2001;98:1662–1666
  19. Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001;276:41059–41063
  20. Soejima K, Mimura N, Hirashima M, Maeda H, Hamamoto T, Nakagaki T, et al.  A novel human metalloprotease synthesized in the liver and secreted into the blood (possibly, the von Willebrand factor-cleaving protease). J Biochem (Tokyo). 2001;130:475–480
  21. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lämmle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1997;89:3097–3103
  22. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, et al.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413:488–494
  23. Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, et al.  Unusually large plasma factor VIII (von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura). N Engl J Med. 1982;307:1432–1435
  24. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347:589–600
  25. Novitzky N, Jacobs P, Rosenstrauch W. The treatment of thrombotic thrombocytopenic purpura (Plasma infusion or exchange?). Br J Haematol. 1994;87:317–320
  26. Coppo P, Bussel A, Charrier S, Adrie C, Galicier L, Boulanger E, et al.  High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome. Medicine (Baltimore). 2003;82:27–38
  27. Pereira A, Mazzara R, Monteagudo J, Sanz C, Puig L, Martinez A, et al.  Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (A multivariate analysis of factors predicting the response to plasma exchange). Ann Hematol. 1995;70:319–323
  28. Sarode R, Gottschall JL, Aster RH, McFarland JG. Thrombotic thrombocytopenic purpura (Early and late responders). Am J Hematol. 1997;4:102–107
  29. Bell WR. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome relapse (Frequency, pathogenesis, and meaning). Semin Hematol. 1997;34:134–139
  30. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int. 2001;60:831–846
  31. George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood. 2000;96:1223–1229
  32. Allford SL, Hunt BJ, Rose P, Machin SJ. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol. 2003;120:556–573
  33. Chopek M, McCullough J. Protein and biochemical changes during plasma exchange. In:  Berkman EM,  Umlas J editor. Therapeutic Hemapheresis. Washington, DC: American Association of Blood Banks; 1980;p. 13–52
  34. AABB Extracorporeal Therapy Committee . Guidelines for Therapeutic Hemapheresis (1992–1993). Bethesda, MD: American Association of Blood Banks; 1992;
  35. Vesely SK, George JN, Lämmle B, Studt JD, Alberio L, El-Harake MA, et al.  ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (Relation to presenting features and clinical outcomes in a prospective cohort of 142 patients). Blood. 2003;102:60–68
  36. Rock GA. Management of thrombotic thrombocytopenic purpura. Br J Haematol. 2000;109:496–507
  37. Bandarenko N, Brecher ME. United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG) (Multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange). J Clin Apheresis. 1998;13:133–141
  38. Moake JL, Byrnes JJ, Troll JH, Rudy CK, Hong SL, Weinstein MJ, et al.  Effects of fresh-frozen plasma and its cryosupernatant fraction on von Willebrand factor multimeric forms in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1985;65:1232–1236
  39. Allford SL, Harrison P, Lawrie AS, Liesner R, MacKie IJ, Machin SJ. Von Willebrand factor-cleaving protease activity in congenital thrombotic thrombocytopenic purpura. Br J Haematol. 2000;111:1215–1222
  40. Byrnes JJ, Moake JL, Klug P, Periman P. Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura. Am J Hematol. 1990;34:169–174
  41. Owens MR, Sweeney JD, Tahhan RH, Fortkolt P. Influence of type of exchange fluid on survival in therapeutic apheresis for thrombotic thrombocytopenic purpura. J Clin Apheresis. 1995;10:178–182
  42. Rock G, Shumak KH, Sutton DM, Buskard NA, Nair RC. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group. Br J Haematol. 1996;94:383–386
  43. Rock GA  Canadian Apheresis Group . Treatment of thrombotic thrombocytopenic purpura with plasma exchange using fresh frozen plasma or cryosupernatant plasma (Variation in metalloprotease and vWF levels). 2003; 14th Congress of the European Society for Hemapheresis Prague, Czech Republic, September 10–13, (abstr)
  44. Zeigler ZR, Shadduck RK, Gryn JF, Rintels PB, George JN, Besa EC, et al.  Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP). J Clin Apheresis. 2001;16:19–22
  45. Röthele E, Krumme B, Rump LC. Design of the prospective randomized study for the treatment of patients with thrombotic microangiopathy. PRODROMI Study Group. Ther Apheresis. 2000;4:327–331
  46. Klein HG, Dodd RY, Dzik WH, Luban NL, Ness PM, Pisciotto P, et al.  Current status of solvent/detergent-treated frozen plasma. Transfusion. 1998;38:102–107
  47. Evans G, Llewelyn C, Luddington R, Baglin TP, Williamson LM. Solvent/detergent fresh frozen plasma as primary treatment of acute thrombotic thrombocytopenic purpura. Clin Lab Haematol. 1999;21:119–123
  48. Harrison CN, Lawrie AS, Iqbal A, Hunter A, Machin SJ. Plasma exchange with solvent/detergent-treated plasma of resistant thrombotic thrombocytopenic purpura. Br J Haematol. 1996;94:756–758
  49. Rock G, Clark B, Sutton D. The Canadian Apheresis Registry. Transfus Apheresis Sci. 2003;29:167–177
  50. Aznar JA, Molina R, Montoro JM. Factor VIII/von Willebrand factor complex in methylene blue-treated fresh plasma. Transfusion. 1999;39:748–750
  51. Cardigan R, Allford S, Williamson L. Levels of von Willebrand factor-cleaving protease are normal in methylene blue-treated fresh-frozen plasma. Br J Haematol. 2002;117:253–254
  52. de la Rubia J, Arriaga F, Linares D, Larrea L, Carpio N, Marty ML, et al: Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. Br J Haematol 114: 721–723, 2010
  53. Ziselman EM, Bongiovanni MB, Wurzel HA. The complications of therapeutic plasma exchange. Vox Sang. 1984;46:270–276
  54. Sutton DM, Nair RC, Rock G. Complications of plasma exchange. Transfusion. 1989;29:124–127
  55. Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange (Complications and management). Am J Kidney Dis. 1994;23:817–827
  56. McLeod BC, Sniecinski I, Ciavarella D, Owen H, Price TH, Randels MJ, et al.  Frequency of immediate adverse effects associated with therapeutic apheresis. Transfusion. 1999;39:282–288
  57. Rizvi MA, Vesely SK, George JN, Chandler L, Duvall D, Smith JW, et al.  Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura- hemolytic-uremic syndrome. Transfusion. 2000;40:896–901
  58. McMinn JR, Thomas IA, Terrell DR, Duvall D, Vesely SK, George JN. Complications of plasma exchange in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (A study of 78 additional patients). Transfusion. 2003;43:415–416
  59. Biesert L, Suhartono H. Solvent/detergent treatment of human plasma—A very robust method for virus inactivation. Validated virus safety of OCTAPLAS. Vox Sang. 1998;74(suppl 1):207–212
  60. Horowitz B, Lazo A, Grossberg H, Page G, Lippin A, Swan G. Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma. Vox Sang. 1998;74(suppl 1):203–206
  61. Sharma AD, Sreeram G, Erb T, Grocott HP. Solvent-detergent-treated fresh frozen plasma (A superior alternative to standard fresh frozen plasma). J Cardiothorac Vasc Anesth. 2000;14:712–717
  62. Baudoux E, Margraff U, Coenen A, Jacobs X, Strivay M, Lungu C, et al.  Hemovigilance (Clinical tolerance of solvent-detergent treated plasma). Vox Sang. 1998;74(suppl 2):237–239
  63. The Serious Hazard of Transfusion Steering Group . Serious Hazards of Transfusion ((SHOT)—Annual Report 2000–2001). 2002; Manchester, England
  64. Popovsky MA, Abel MD, Moore SB. Transfusion-related acute lung injury associated with passive transfer of antileukocyte antibodies. Am Rev Respir Dis. 1983;128:185–189
  65. Weber JG, Warner MA, Moore SB. What is the incidence of perioperative transfusion-related acute lung injury. Anesthesiology. 1995;82:789; (letter)
  66. Silliman CC, Boshkov LK, Mehdizadehkashi Z, Elzi DJ, Dickey WO, Podlosky L, et al.  Transfusion-related acute lung injury (Epidemiology and a prospective analysis of etiologic factors). Blood. 2003;101:454–462
  67. Yarranton H, Cohen H, Pavord SR, Benjamin S, Hagger D, Machin SJ. Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol. 2003;121:778–785
  68. Furlan M, Lämmle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uremic syndrome (The role of von Willebrand factor-cleaving protease). Best Pract Res Clin Haematol. 2001;14:437–454
  69. Bianchi V, Robles R, Alberio L, Furlan M, Lämmle B. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders (A severely deficient activity is specific for thrombotic thrombocytopenic purpura). Blood. 2002;100:710–713
  70. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies (A study of 111 cases). Blood. 2001;98:1765–1772
  71. Mori Y, Wada H, Gabazza EC, Minami N, Nobori T, Shiku H, et al.  Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity. Transfusion. 2002;42:572–580
  72. Studt JD, Kremer Hovinga JA, Alberio L, Bianchi V, Lämmle B. Von Willebrand factor-cleaving protease (ADAMTS-13) activity in thrombotic microangiopathies (Diagnostic experience 2001/2002 of a single research laboratory). Swiss Med Wkly. 2003;133:325–332
  73. Winkler A, Kremer Hovinga JA, Bianchi V, Studt JD, Lämmle B. Schistocytic anaemia, severe thrombocytopenia, and renal dysfunction (Thrombotic microangiopathy due to severe acquired ADAMTS-13 deficiency). Haemostaseologie. 2003;3:103–108
  74. Fontana S, Gerritsen HE, Kremer Hovinga J, Furlan M, Lämmle B. Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease. Br J Haematol. 2001;113:100–102
  75. Buchta C, Macher M, Bieglmayer C, Höcker P, Dettke M. Reduction of adverse citrate reactions during autologous large-volume PBPC apheresis by continuous infusion of calcium-gluconate. Transfusion. 2003;43:1615–1621
  76. Furlan M, Robles R, Morselli B, Sandoz P, Lämmle B. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost. 1999;81:8–13
  77. Knöbl P, Haas M, Laczika K, Varadi K, Turecek PL. Immunoadsorption for the treatment of a patient with severe thrombotic thrombocytopenic purpura resistant to plasma exchange (Kinetics of an inhibitor of ADAMTS13). J Thromb Haemost. 2003;1:187–189
  78. Mansouri Taleghani B, Grossmann R. Treatment of patients with factor VIII autoantibodies by staphylococcal protein A-based immunoadsorption and immunosuppression. Br J Haematol. 2001;114:956–958
  79. Langer F, Bergmann F, Budde U, Hegewisch-Becker S, Hossfeld DK. Prolonged inhibition of von Willebrand factor-cleaving protease after splenectomy in a 22-year-old patient with acute and plasma refractory thrombotic thrombocytopenic purpura. Br J Haematol. 2002;118:271–274
  80. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion. 1985;25:573–577
  81. Wallis JP, Lubenko A, Wells AW, Chapman CE. Single hospital experience of TRALI. Transfusion. 2003;43:1053–1059
  82. Antoine G, Zimmermann K, Plaimauer B, Grillowitzer M, Studt JD, Lämmle B, et al.  ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13. Br J Haematol. 2003;120:821–824

PII: S0037-1963(03)00283-X

doi: 10.1053/j.seminhematol.2003.10.010

Seminars in Hematology
Volume 41, Issue 1 , Pages 48-59 , January 2004

Article Tools

* Image Usage & Resolution